More on CLLS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.09 |
|
|||
| Open | $3.09 | ||||
| 52 Wk High | $37.55 | ||||
| 52 Wk Low | $16.35 | ||||
| Day High | $3.09 | ||||
| Day Low | $3.09 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,324 | ||||
- Cellectis receives FDA RMAT designation for blood cancer therapy
- Barclays initiates oncology-focused biotechs with positive outlook
- Barclays Starts Cellectis (CLLS) at Overweight
- Cellectis (CLLS) Tops Q1 EPS by 8c
- Cibus Announces Transfer of Gene-Edited Herbicide Tolerance Traits in Interoc Rice Seeds for Testing and Production
- Cibus elects Thomas Urban to board of directors
- Cibus Announces the Election of Thomas Urban to Board of Directors
- Cellectis (CLLS) Reiterated at Market Outperform by Citizens After MRD Clearance
- Cellectis (CLLS) Reiterated at Market Outperform by Citizens: 2025 Pipeline Updates Good
- Form 20-F Cellectis S.A. For: Dec 31
Entities mentioned with CLLS
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- IPO | View Related Stories »
- Citi | View Related Stories »
- Barclays | View Related Stories »
- S1 | View Related Stories »
- Show More...
